We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

76 hedge funds and large institutions have $202M invested in iShares US Pharmaceuticals ETF in 2013 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 3

29% more capital invested

Capital invested by funds: $157M → $202M (+$45.3M)

28% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 18

21% more funds holding

Funds holding: 63 → 76 (+13)

11.86% more ownership

Funds ownership: 95.09% → 106.95% (+12%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
76
Holders Change
+13
Holders Change %
+20.63%
% of All Funds
2.21%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
18
Increased
23
Reduced
18
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCMG
Clark Capital Management Group
Pennsylvania
+$4.62M
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$2.99M
3
DS
DRW Securities
Illinois
+$2.61M
4
VKH
Virtu KCG Holdings
New York
+$1.82M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.76M

Top Sellers

Rank Fund Capital Flow
1
BCI
Brinker Capital Investments
Pennsylvania
-$2.82M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
-$2.32M
3
Morgan Stanley
Morgan Stanley
New York
-$877K
4
Bank of America
Bank of America
North Carolina
-$665K
5
SG Americas Securities
SG Americas Securities
New York
-$637K
Name Holding Trade Value Shares
Change 		Change in
Stake
CFA
26
Cahill Financial Advisors
Minnesota
$1.47M +$1.4M +37,311 New
Goldman Sachs
27
Goldman Sachs
New York
$1.42M +$922K +24,564 +215%
DADC
28
D.A. Davidson & Co
Montana
$1.33M -$46.3K -1,233 -4%
CPC
29
Cookson Peirce & Co
Pennsylvania
$1.3M +$1.24M +33,102 New
LSA
30
L & S Advisors
California
$861K +$821K +21,873 New
WA
31
WESPAC Advisors
California
$851K +$125K +3,330 +18%
SI
32
SII Investments
Wisconsin
$821K – – –
HSBC Holdings
33
HSBC Holdings
United Kingdom
$765K – – –
ACM
34
Avalon Capital Management
California
$756K – – –
VFS
35
VSR Financial Services
Kansas
$737K +$42.8K +1,140 +6%
NES
36
New England Securities
New York
$721K +$142K +3,798 +26%
CAN
37
Cetera Advisor Networks
California
$711K +$215K +5,739 +47%
PAG
38
Private Advisor Group
New Jersey
$665K +$634K +16,890 New
AMG
39
Asset Management Group
Connecticut
$586K +$171K +4,563 +44%
NPC
40
National Planning Corporation
California
$533K +$81.7K +2,178 +19%
US Bancorp
41
US Bancorp
Minnesota
$508K – – –
TRCT
42
Tower Research Capital (TRC)
New York
$506K +$482K +12,852 New
TYCC
43
Texas Yale Capital Corp
Florida
$440K – – –
WA
44
WFG Advisors
Texas
$396K -$60.2K -1,605 -14%
UCFA
45
United Capital Financial Advisors
Texas
$354K +$338K +9,000 New
Ameriprise
46
Ameriprise
Minnesota
$324K +$29.1K +777 +10%
William Blair & Company
47
William Blair & Company
Illinois
$307K – – –
GA
48
Gateway Advisory
New Jersey
$306K +$292K +7,770 New
CS
49
Credit Suisse
Switzerland
$291K +$6.75K +180 +2%
AFG
50
Arkansas Financial Group
Arkansas
$272K +$259K +6,903 New
1
2
3 4

IHE Hedge Fund Activity: Q4 2013 in Review

76 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2013, worth a combined $202M — up 29% from $157M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new IHE positions and 3 closed out — a net gain of 15 holders — while 23 added to existing stakes and 18 trimmed.

The largest buyer was Clark Capital Management Group, opening a new position worth an estimated $4.62M. The largest seller was Brinker Capital Investments, cutting an estimated $2.82M.

  • 76 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2013, up from 63 in Q3 2013.
  • Funds reported $202M of iShares US Pharmaceuticals ETF stock for Q4 2013, up 29% quarter-over-quarter.
  • 18 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2013 and 3 closed out, a net change of +15 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q4 2013 was Clark Capital Management Group, an estimated $4.62M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q4 2013 was Brinker Capital Investments, an estimated $2.82M sold.

Based on aggregated 13F filings for Q4 2013.